查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1698054

乳癌液體切片檢測設備市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、循環生物標記、應用、區域及競爭情況細分，2020-2030 年預測）

Breast Cancer Liquid Biopsy Testing Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offerings, By Circulating Biomarker, By Application, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球乳癌液體活體組織切片檢測設備市場價值為 8.3536 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 17.20%。液體活體組織切片是乳癌診斷和治療領域的寶貴資產。透過液體活體組織切片分析突變有助於根據患者腫瘤特定的基因變化來確定針對個別患者的標靶治療方法。例如，對於轉移性乳癌患者，篩檢約 40% HR 陽性腫瘤中發現的 PIK3CA 突變有助於確定最有效的治療途徑。例如，根據美國癌症協會 (ASC) 2023 年報告，乳癌仍然是美國女性中最常見的癌症（不包括皮膚癌）。它佔每年診斷出的所有女性癌症的30%。為了降低乳癌的發病率和死亡率，政府發布了政策並發布了法律來支持患者承擔診斷和治療的費用。此外，根據世界衛生組織2023年的報告，每年診斷出的乳癌病例超過230萬例，是成年人中最常見的癌症。然而，約 80% 的乳癌相關死亡發生在中低收入國家。

市場概覽
預測期 2026-2030
2024 年市場規模 8.3536億美元
2030年市場規模 21.4906億美元
2025-2030 年複合年成長率 17.20％
成長最快的領域 循環腫瘤DNA
最大的市場 北美洲

主要市場促進因素

癌症檢測技術的進步

主要市場挑戰

敏感性和特異性有限

主要市場趨勢

與傳統診斷的整合

目錄

第 1 章：產品概述

第 2 章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球乳癌液體切片檢測設備市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品分類（分析試劑盒、儀器）
    • 依循環生物標記（循環腫瘤DNA、循環腫瘤細胞、細胞外囊泡）
    • 按應用（癌症應用、非癌症應用）
    • 按地區
    • 按公司分類（2022 年）
  • 產品市場圖
    • 按奉獻
    • 透過循環生物標記
    • 按應用
    • 按地區

第6章：北美乳癌液體切片檢測設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第7章：歐洲乳癌液體切片檢測設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 法國
    • 義大利
    • 西班牙

第8章：亞太地區乳癌液體切片檢測設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 日本
    • 印度
    • 澳洲
    • 韓國

第9章：南美洲乳癌液體切片檢測設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲乳癌液體切片檢測設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 合併與收購
  • 產品發布

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • A Menarini AG
  • NeoGenomics Laboratories Inc
  • F Hoffmann-La Roche AG
  • Myriad Genetics Inc
  • QIAGEN NV
  • Biocept Inc
  • Sysmex Corp
  • Fluxion Biosciences Inc
  • Thermo Fisher Scientific Inc
  • Epic Sciences Inc

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 20610

Global Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 835.36 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 17.20% through 2030. Liquid biopsy serves as a valuable asset in the realm of breast cancer diagnosis and treatment. The analysis of mutations through liquid biopsy aids in the identification of targeted therapies tailored to individual patients based on their tumor-specific genetic alterations. To illustrate, in the case of patients grappling with metastatic breast cancer, screening for the PIK3CA mutation, which is found in around 40% of HR-positive tumors, assists in determining the most effective treatment path. For instance, according to the American Society of Cancer (ASC) Report 2023, breast cancer remains the most common cancer among women in the United States, excluding skin cancers. It accounts for 30% of all female cancers diagnosed annually. In an effort to reduce the prevalence and mortality rates of breast cancer, the government has implemented policies and introduced laws to support patients with the costs of diagnosis and treatment. Also, according to the World Health Organization 2023 report, more than 2.3 million cases of breast cancer are diagnosed annually, making it the most prevalent cancer among adults. However, approximately 80% of breast cancer-related deaths occur in low- and middle-income countries.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 835.36 Million
Market Size 2030USD 2149.06 Million
CAGR 2025-203017.20%
Fastest Growing SegmentCirculating Tumor DNA
Largest MarketNorth America

Key Market Drivers

Advancements in Cancer Detection Technology

The landscape of cancer detection and diagnosis is evolving rapidly, and one area of remarkable progress is the development of liquid biopsy testing devices. These devices, which have gained prominence in the healthcare industry, are offering a non-invasive, highly sensitive, and patient-friendly approach to detect and monitor cancer, with breast cancer being a significant focus.

One of the keyways advancements in cancer detection technology are boosting the growth of the global breast cancer liquid biopsy market is by enhancing sensitivity and specificity. Liquid biopsies can now detect minute traces of circulating tumor DNA (ctDNA) or other biomarkers in a patient's bloodstream. This increased sensitivity ensures that even small tumors or minimal residual disease (MRD) can be detected accurately, which was often challenging with traditional diagnostic methods.

Key Market Challenges

Limited Sensitivity and Specificity

While liquid biopsy testing devices have advanced considerably, they may still face challenges related to sensitivity and specificity. Detecting circulating tumor DNA (ctDNA) or other biomarkers in the bloodstream can be challenging, especially for small or early-stage tumors. Improving the sensitivity and specificity of these tests remains a priority for the industry.

Key Market Trends

Integration with Conventional Diagnostics

The trend is moving towards the integration of liquid biopsy testing devices with traditional diagnostic methods. Combining liquid biopsies with imaging and tissue biopsies can provide a more comprehensive understanding of the disease. This integrated approach offers greater diagnostic accuracy and opens up new avenues for treatment decisions.

Key Market Players

  • A Menarini AG
  • NeoGenomics Laboratories Inc
  • F Hoffmann-La Roche AG
  • Myriad Genetics Inc
  • QIAGEN NV
  • Biocept Inc
  • Sysmex Corp
  • Fluxion Biosciences Inc
  • Thermo Fisher Scientific Inc
  • Epic Sciences Inc

Report Scope:

In this report, the Global Breast Cancer Liquid Biopsy Testing Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Liquid Biopsy Testing Devices Market, By Offerings:

  • Assay & Reagents Kits
  • Instruments

Breast Cancer Liquid Biopsy Testing Devices Market, By Circulating Biomarker:

  • Circulating Tumor DNA
  • Circulating Tumor Cell
  • Extracellular Vesicles

Breast Cancer Liquid Biopsy Testing Devices Market, By Application:

  • Cancer Applications
  • Non-Cancer Applications

Breast Cancer Liquid Biopsy Testing Devices Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Cancer Liquid Biopsy Testing Devices Market.

Available Customizations:

Global Breast Cancer Liquid Biopsy Testing Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Cancer Liquid Biopsy Testing Devices Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Offerings (Assay & Reagents Kits, Instruments)
    • 5.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
    • 5.2.3. By Application (Cancer Applications, Non-Cancer Applications)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Offerings
    • 5.3.2. By Circulating Biomarker
    • 5.3.3. By Application
    • 5.3.4. By Region

6. North America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Offerings (Assay & Reagents Kits, Instruments)
    • 6.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
    • 6.2.3. By Application (Cancer Applications, Non-Cancer Applications)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Offerings
        • 6.3.1.2.2. By Circulating Biomarker
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Offerings
        • 6.3.2.2.2. By Circulating Biomarker
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Offerings
        • 6.3.3.2.2. By Circulating Biomarker
        • 6.3.3.2.3. By Application

7. Europe Breast Cancer Liquid Biopsy Testing Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Offerings (Assay & Reagents Kits, Instruments)
    • 7.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
    • 7.2.3. By Application (Cancer Applications, Non-Cancer Applications)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Offerings
        • 7.3.1.2.2. By Circulating Biomarker
        • 7.3.1.2.3. By Application
    • 7.3.2. United Kingdom Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Offerings
        • 7.3.2.2.2. By Circulating Biomarker
        • 7.3.2.2.3. By Application
    • 7.3.3. France Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Offerings
        • 7.3.3.2.2. By Circulating Biomarker
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Offerings
        • 7.3.4.2.2. By Circulating Biomarker
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Offerings
        • 7.3.5.2.2. By Circulating Biomarker
        • 7.3.5.2.3. By Application

8. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Offerings (Assay & Reagents Kits, Instruments)
    • 8.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
    • 8.2.3. By Application (Cancer Applications, Non-Cancer Applications)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Offerings
        • 8.3.1.2.2. By Circulating Biomarker
        • 8.3.1.2.3. By Application
    • 8.3.2. Japan Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Offerings
        • 8.3.2.2.2. By Circulating Biomarker
        • 8.3.2.2.3. By Application
    • 8.3.3. India Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Offerings
        • 8.3.3.2.2. By Circulating Biomarker
        • 8.3.3.2.3. By Application
    • 8.3.4. Australia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Offerings
        • 8.3.4.2.2. By Circulating Biomarker
        • 8.3.4.2.3. By Application
    • 8.3.5. South Korea Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Offerings
        • 8.3.5.2.2. By Circulating Biomarker
        • 8.3.5.2.3. By Application

9. South America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Offerings (Assay & Reagents Kits, Instruments)
    • 9.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
    • 9.2.3. By Application (Cancer Applications, Non-Cancer Applications)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Offerings
        • 9.3.1.2.2. By Circulating Biomarker
        • 9.3.1.2.3. By Application
    • 9.3.2. Argentina Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Offerings
        • 9.3.2.2.2. By Circulating Biomarker
        • 9.3.2.2.3. By Application
    • 9.3.3. Colombia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Offerings
        • 9.3.3.2.2. By Circulating Biomarker
        • 9.3.3.2.3. By Application

10. Middle East and Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Offerings (Assay & Reagents Kits, Instruments)
    • 10.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
    • 10.2.3. By Application (Cancer Applications, Non-Cancer Applications)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Offerings
        • 10.3.1.2.2. By Circulating Biomarker
        • 10.3.1.2.3. By Application
    • 10.3.2. Saudi Arabia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Offerings
        • 10.3.2.2.2. By Circulating Biomarker
        • 10.3.2.2.3. By Application
    • 10.3.3. UAE Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Offerings
        • 10.3.3.2.2. By Circulating Biomarker
        • 10.3.3.2.3. By Application
    • 10.3.4. Kuwait Breast Cancer Liquid Biopsy Testing Devices Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Offerings
        • 10.3.4.2.2. By Circulating Biomarker
        • 10.3.4.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. A Menarini AG
  • 14.2. NeoGenomics Laboratories Inc
  • 14.3. F Hoffmann-La Roche AG
  • 14.4. Myriad Genetics Inc
  • 14.5. QIAGEN NV
  • 14.6. Biocept Inc
  • 14.7. Sysmex Corp
  • 14.8. Fluxion Biosciences Inc
  • 14.9. Thermo Fisher Scientific Inc
  • 14.10. Epic Sciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer